Allt inom Listing Regulation
Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation
- Nanexa’s atomic layer deposition (ALD) platform PharmaShell® demonstrably improves the pharmacokinetic profile of semaglutide injections.
- Significantly smoother plasma concentration curve could mitigate many common side effects of GLP-1 drugs.
Nanexa AB changes Certified Adviser to Tapper Partners AB
Nanexa AB announces today that the company is changing its Certified Adviser to Tapper Partners AB.